> GlaxoSmithKline says it will apply for European marketing approval for a new vaccine to prevent bird flu in October. Glaxo started clinical trials in March. Report

> Serono announced that a 12-week study of Raptiva demonstrated a significant improvement among patients with psoriasis, even among patients who were resistant to other therapies. The drug was well tolerated among trial subjects. Psoriasis is a chronic skin condition that requires long-term therapy. Serono expects sales of Raptiva to grow from $33 million last year to $250 million in four years. Report

> Blaming unexpectedly low revenue from its genomics division, Gene Logic has withdrawn its advisory for 2006 and 2007, sending shares down. Report

> Human Genome Sciences says a Phase II trial of LymphoStat-B demonstrates it was effective in reducing the disease activity of systemic lupus erythematosus and was safe and well tolerated. A Phase III trial is planned. Release

> GenMab shares were buoyed by news that a small Phase II study of AMG 714 demonstrated efficacy against rheumatoid arthritis. Report

> Takeda's full pipeline of experimental therapies has turned analysts bullish about the company's future prospects. Report (WSJ sub. req.)

> Molecular Insight announced that the FDA has put its cancer drug Azedra on the regulator's fast track and begun a Phase I trial. Report

> Anticipation is growing for an FDA decision on Oxymorphone ER, a pain med from Penwest and Endo. Report

> Chutes & Ladders: Dr. Hamish Cameron has been appointed CEO of CAT Ltd. Release

> ISTA Pharmaceuticals will issue $40 million in notes. Report

> New studies show that Orencia and Rituxan both offer rheumatoid arthritis patients substantial benefits. Report

> A new study shows that the old cancer drug Cytoxan has some effect as a therapy for scleroderma, a disfiguring autoimmune disease. Article

> An independent panel has recommended that Neopharm continue a late-stage trial of its experimental therapy for brain tumors. Release

> And Finally… The FDA is developing a new Web-based reporting system for adverse events. Report